Change search
ReferencesLink to record
Permanent link

Direct link
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
AstraZeneca, S-15185 Sodertalje, Sweden.;Univ Oslo, Fac Med, N-0424 Oslo, Norway..
Statisticon AB, S-75322 Uppsala, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden.;AZ R&D, Med Evidence & Observat Res, Molndal, Sweden..
Show others and affiliations
2016 (English)In: Clinical drug investigation, ISSN 1173-2563, E-ISSN 1179-1918, Vol. 36, no 3, 225-233 p.Article in journal (Refereed) PublishedText
Abstract [en]

Background and Objectives Statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) are unrelated. Many patients initiated on statins experience a paradoxical decrease in HDL-C. The aim of this study was to evaluate the association between a decrease in HDL-C and risk of major adverse cardiovascular events (MACE). Methods Data from 15,357 primary care patients initiated on statins during 2004-2009 were linked with data from mandatory national hospital, drug-dispensing, and cause-of-death registers, and were grouped according to HDL-C change: decreased >= 0.1 mmol/L, unchanged +/- 0.1 or >= 0.1 mmol/L increased. To evaluate the association between decrease in HDL-C and risk of MACE, a sample of propensity score-matched patients from the decreased and unchanged groups was created, using the latter group as reference. MACE was defined as myocardial infarction, unstable angina pectoris, ischaemic stroke, or cardiovascular mortality. Cox proportional hazards models were used to estimate relative risks. Results HDL-C decreased in 20 %, was unchanged in 58%, and increased in 22 % of patients initiated on statin treatment (96 % treated with simvastatin). The propensity score-matched sample comprised 5950 patients with mean baseline HDL-C and LDL-C of 1.69 and 4.53 mmol/L, respectively. HDL-C decrease was associated with 56 % higher MACE risk (hazard ratio 1.56; 95 % confidence interval 1.12-2.16; p < 0.01) compared with the unchanged HDL-C group. Conclusions Paradoxical statin-induced reduction in HDL-C was relatively common and was associated with increased risk of MACE.

Place, publisher, year, edition, pages
2016. Vol. 36, no 3, 225-233 p.
National Category
Pharmacology and Toxicology
URN: urn:nbn:se:uu:diva-281478DOI: 10.1007/s40261-015-0372-9ISI: 000370841400006PubMedID: 26718960OAI: diva2:915371
Available from: 2016-03-30 Created: 2016-03-24 Last updated: 2016-03-30Bibliographically approved

Open Access in DiVA

fulltext(607 kB)60 downloads
File information
File name FULLTEXT01.pdfFile size 607 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sundstrom, JohanJohansson, Gunnar
By organisation
UCR-Uppsala Clinical Research CenterFamily Medicine and Preventive Medicine
In the same journal
Clinical drug investigation
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 60 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 122 hits
ReferencesLink to record
Permanent link

Direct link